Tandem Diabetes Care Inc
TNDM
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
117.4% downsideOvervalued by 117.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.18 Billion |
|---|---|
| Enterprise Value | $1.74 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.04 |
| Beta | 1.64 |
| Outstanding Shares | 68,397,000 |
Return
| Return on Equity | -71.41% |
|---|---|
| Return on Assets | -8.20% |
| Return on Invested Capital | -9.63% |
Valuation & Multiples
| P/E Ratio | -12.44 |
|---|---|
| PEG | 14.75 |
| Price to Sales | 1.2 |
| Price to Book Ratio | 18.03 |
| Enterprise Value to Revenue | 1.7 |
| Enterprise Value to EBIT | -19.99 |
| Enterprise Value to Net Income | -19 |
| Total Debt to Enterprise | 0.43 |
| Debt to Equity | 5.62 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0646▼ 4.01% |
|---|---|
| Total Calls | 5,465,470▲ 84.06% |
| Total Puts | 352,900▲ 13.54% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 115.65%▲ 4.99% |
|---|---|
| Total Invested | $1.51B▼ 8.34% |
| Investors Holding | 284▲ 3.00% |
ESG Score
No data
About Tandem Diabetes Care Inc
1,600 employees
CEO: John Sheridan Tandem Diabetes Care, Inc. is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach t...
Relevant Senate Committees
This powerful committee controls taxation, trade, and entitlement spending, including Medicare and Medicaid. Decisions on Medicare pricing and coverage for medical devices, as well as corporate tax policy, directly impact Tandem Diabetes Care's revenue and profitability.
This committee directly allocates discretionary federal spending. Its subcommittees determine precise funding for healthcare programs (e.g., VA, NIH research) that could involve purchasing or supporting the use of Tandem Diabetes Care's products.
This committee directly regulates the FDA, which is the primary regulatory body for medical devices in the US. FDA approval and oversight are essential for Tandem Diabetes Care's product development and market access.
This committee's oversight of antitrust laws and intellectual property (IP) is critically important. Patent protection is vital for medical device companies like Tandem Diabetes Care, and antitrust decisions can impact mergers and market competition.
This committee directly oversees the Department of Veterans Affairs (VA), which is a major healthcare provider and potential purchaser of medical devices like those made by Tandem Diabetes Care. Funding decisions directly impact government healthcare contractors.